Glenmark is now the first of the New Generation $1 billion Indian corporates who cnan swing a global giant on its toes for a day of waltzing than a 5 minute bollywood snapshot. After India's PR failed in the last 20 years to read the western mind and the trauma in the markets there, the new generation deals have started to look creamier and thicker with the Glenmark signing. The GBR 500 molecule has passed some trtials for human disorders like COPD, IBD and ius ready to go big, fetching nearly Rs 400 crores plus lifelong marketing rights across 5 continents for the Indian drug maker. 

the sector has earlier belied hopes for well over 5 years following textile exports and auto ancilliaries into oblivion almost, before being brought back with smaller marketing arrangements with Biocon and Sun. The SUn MSD deal could potentially be bigger but is just a signing, while the Glenmark deal is here and now for a drug ready to enter the marrket. Glenmark has also upgraded its margins in Q4 with a $50 million profit on $275 million sales ready to enter the big league and now ahead of Sri Aurobindo and maybe even Ranbaxy around the bend

Posted via email from The investment blog on Post